Sagimet Biosciences prices $164.5M stock offering

Sagimet Biosciences Inc. entered into an underwriting agreement for an underwritten public offering of 29,166,700 shares of its Series A common stock at $6.00 per share.

Rhea-AI Filing Summary

Sagimet Biosciences Inc. entered into an underwriting agreement for an underwritten public offering of 29,166,700 shares of its Series A common stock at $6.00 per share. The Company expects to receive $164.5 million in net proceeds after underwriting discounts and commissions.

The Company plans to use the proceeds, together with existing cash, cash equivalents and marketable securities, to fund a Phase 3 clinical trial for denifanstat in acne, advance TVB-3567 through Phase 2 topline results, move a topical FASN inhibitor to IND submission, and for general corporate purposes including additional clinical development, working capital and operating expenses.

Insights

Biopharma capital markets analyst

Sagimet secures $164.5M net equity financing to fund late-stage trials.

Sagimet Biosciences is raising equity capital through an underwritten offering of 29,166,700 Series A common shares at $6.00 per share, yielding expected net proceeds of $164.5 million. The deal is conducted off an effective shelf registration statement on Form S-3.

The Company earmarks this capital to fund a Phase 3 denifanstat acne trial, advance TVB-3567 to Phase 2 topline, and progress a topical FASN inhibitor to IND submission, plus general corporate uses. This links the raise directly to clinical pipeline advancement rather than unspecified purposes.

While equity offerings can be dilutive, they also strengthen funding for costly late-stage studies. Actual impact depends on execution of the Phase 3 acne trial, Phase 2 TVB-3567 data, and regulatory milestones tied to the topical FASN inhibitor, as disclosed in future company filings.

8-K Event Classification

2 items: 1.01, 9.01

2 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Shares offered: 29,166,700 shares Offering price: $6.00 per share Net proceeds: $164.5 million +2 more

5 metrics

Shares offered 29,166,700 shares Underwritten offering of Series A common stock

Offering price $6.00 per share Price for Series A common stock in the offering

Net proceeds $164.5 million Expected net proceeds after underwriting discounts and commissions

Shelf registration Form S-3 No. 333-281582 Effective shelf registration statement used for the offering

Underwriting agreement date April 27, 2026 Date of underwriting agreement with the underwriters

Key Terms

underwriting agreement, underwritten offering, shelf registration statement, Phase 3 clinical trial, +2 more

6 terms

underwriting agreement financial

"entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC"

An underwriting agreement is a contract where a company selling new stocks or bonds hires financial firms to buy those securities and resell them to investors. It matters because the agreement sets the offering price, number of securities, fees and which party bears the risk if sales fall short—think of it as a promise that the sale will happen and a roadmap investors can use to understand how the new securities reach the market.

underwritten offering financial

"relating to an underwritten offering (the “Offering”) of 29,166,700 shares"

An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.

shelf registration statement regulatory

"pursuant to the Company’s effective shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

Phase 3 clinical trial medical

"to fund a Phase 3 clinical trial for denifanstat in acne"

A phase 3 clinical trial is a large-scale study that tests a new medical treatment or drug to determine if it is safe and effective for widespread use. It often involves hundreds or thousands of participants and compares the new treatment to existing options or a placebo. For investors, the results of this phase are crucial, as successful outcomes can lead to regulatory approval and commercial success, while failures may halt development.

IND submission medical

"advance a topical formulation FASN inhibitor to IND submission"

An IND submission is an application a drug developer files with a regulatory authority (for example, the U.S. Food and Drug Administration) asking permission to start testing a new medicine in humans. It shows the company’s lab and safety data and a plan for clinical studies; for investors, an accepted IND is like a green light to move from research to trials, reducing development risk and unlocking value milestones.

joint book-running managers financial

"acted as joint book-running managers for the Offering"

Joint book-running managers are the lead banks or financial firms responsible for organizing and overseeing the sale of a large financial offering, such as a company’s stock or bonds. They coordinate efforts to set the price, attract investors, and ensure the offering is successful. Their role is important to investors because they help ensure the offering is well-managed, properly priced, and accessible to a wide range of buyers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity offering did Sagimet Biosciences (SGMT) announce in this 8-K?

Sagimet Biosciences announced an underwritten public offering of 29,166,700 shares of its Series A common stock at $6.00 per share. The transaction is conducted under its effective Form S-3 shelf registration statement declared effective in August 2024.

How much cash will Sagimet Biosciences (SGMT) receive from the offering?

Sagimet Biosciences expects net proceeds of $164.5 million from the offering after underwriting discounts and commissions. This cash will be combined with existing cash, cash equivalents and marketable securities to support clinical development and general corporate purposes.

How will Sagimet Biosciences (SGMT) use the equity offering proceeds?

Sagimet plans to use proceeds to fund a Phase 3 clinical trial for denifanstat in acne, advance TVB-3567 through Phase 2 topline results, progress a topical FASN inhibitor to IND submission, and cover general corporate needs such as additional clinical development, working capital and operating expenses.

Which banks are managing Sagimet Biosciences’ (SGMT) equity offering?

Leerink Partners, TD Securities (USA) and Guggenheim Securities are joint book-running managers for the Sagimet offering, alongside Oppenheimer & Co., Canaccord Genuity, H.C. Wainwright and JonesTrading as co-lead managers. They underwrite and distribute the 29,166,700 Series A common shares.

What agreement governs Sagimet Biosciences’ (SGMT) new stock offering?

The offering is governed by an underwriting agreement dated April 27, 2026 between Sagimet and several underwriters. It includes customary representations, warranties, closing conditions, indemnification provisions and termination rights, and is filed as Exhibit 1.1, with a related legal opinion as Exhibit 5.1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/28/2026 - 07:01 AM Learn about SEC filing dates

false 0001400118 0001400118 2026-04-27 2026-04-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 27, 2026

SAGIMET BIOSCIENCES INC.

(Exact name of registrant as specified in its charter)

Delaware	001-41742	20-5991472
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Sagimet Biosciences Inc.

155 Bovet Road, Suite 303,

San Mateo, California 94402

(Address of principal executive offices, including zip code)

(650) 561-8600

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trade Symbol(s)	Name of each exchange on which registered
Series A Common Stock, $0.0001 par value per share	SGMT	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01 Entry into a Material Definitive Agreement.

On April 27, 2026, Sagimet Biosciences Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC, and Guggenheim Securities, LLC as representatives of the several underwriters named therein (the “Underwriters”) relating to an underwritten offering (the “Offering”) of 29,166,700 shares (the “Shares”) of the Company’s Series A common stock, par value $0.0001 per share (the “Common Stock”), at an offering price of $6.00 per share.

The net proceeds to the Company from the Offering are expected to be $164.5 million, after deducting underwriting discounts and commissions. The Company intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities to fund a Phase 3 clinical trial for denifanstat in acne, fund TVB-3567 through Phase 2 topline results, advance a topical formulation FASN inhibitor to IND submission and for general corporate purposes, including additional clinical development, working capital and operating expenses.

Leerink Partners LLC, TD Securities (USA) LLC, Guggenheim Securities, LLC and Oppenheimer & Co. Inc. acted as joint book-running managers for the Offering. Canaccord Genuity LLC, H.C. Wainwright & Co., LLC and JonesTrading Institutional Services LLC acted as co-lead managers for the Offering.

The Offering is being made pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-281582), filed with the Securities and Exchange Commission on August 15, 2024 and declared effective on August 26, 2024.

The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties.

The Underwriting Agreement is filed as Exhibits 1.1 to this Current Report on Form 8-K and is incorporated by reference herein. The foregoing descriptions of the terms of the Underwriting Agreement is qualified in its entirety by reference to the exhibit. A copy of the legal opinion and consent of Goodwin Procter LLP relating to the legality of the issuance and sale of the Common Stock in the Offering is attached as Exhibit 5.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Document
1.1		Underwriting Agreement, dated April 27, 2026, by and among the Company and Leerink Partners LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC
5.1		Opinion of Goodwin Procter LLP
23.1		Consent of Goodwin Procter LLP (included in Exhibit 5.1)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Sagimet Biosciences Inc.
Date: April 28, 2026	By:	/s/ David Happel
		David Happel
		Chief Executive Officer

Filing Exhibits & Attachments

5 documents

Other Documents

• EX-1.1 EXHIBIT 1.1 197.5 KB
• EX-5.1 EXHIBIT 5.1 9.8 KB
• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.8 KB